Latest Conference Articles

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Early gut microbiome changes in c-section infants linked to food sensitization at 12 months, highlighting a potential critical intervention window.

Trial data show early microbiome shifts after vaginal microbial transfer in cesarean-delivered infants, with differences in food sensitization at 12 months.

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy.

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Eichenfield speaks in this interview about several key takeaways drawn from her master class in pediatric dermatology at Maui Derm Hawaii.

This segment of an interview from Maui Derm Hawaii, featuring Mark Kaufmann, MD, highlights key advice on AI scribe use and billing effectiveness in dermatology practices.

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.